zydelig
Gilead cancer boss departs after safety concerns halt Zydelig trials
March 18, 2016Medical Communications, Research and Development Gilead Sciences, zydelig
In the wake of the halting of six clinical trials of its blood cancer drug Zydelig due to safety concerns, …
EMA starts review of Gilead Sciences’ Zydelig following safety concerns
March 14, 2016Research and Development, Sales and Marketing EMA, Gilead Sciences, blood cancer, clinical trials, zydelig
Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports …
NICE approves first in new class of leukaemia drugs
September 24, 2015Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig
NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …
NICE wants more answers from Gilead on Zydelig
June 18, 2015Sales and Marketing Gilead, MabThera, NICE, Roche, UK, brett wells, zydelig
The National Institute for Health and Care Excellence has not recommended Gilead’s leukaemia drug Zydelig in draft guidance. But the …
Gilead’s blood cancer pill approved in Europe
September 22, 2014Sales and Marketing CLL, Gilead, blood cancer, fl, idelalisib, oncology, zydelig
Gilead has gained European Commission approval for its new blood cancer pill Zydelig (idelalisib) as it looks to expand further …
EMA approvals for rival blood cancer drugs
July 27, 2014Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig
Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …
FDA approves Gilead’s blood cancer drug
July 24, 2014Research and Development, Sales and Marketing Cancer, FDA, Gilead, blood, follicular lymphoma and small lymphocytic lymphoma, lymphocytic leukaemia, sovaldi, zydelig
The Food and Drug Administration has approved Gilead Sciences new treatment Zydelig (idelalisib) to treat three types of blood cancer. …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
